Stealth BioTherapeutics Corp to Post FY2023 Earnings of ($0.01) Per Share, Jefferies Financial Group Forecasts (NASDAQ:MITO)

Stealth BioTherapeutics Corp (NASDAQ:MITO) – Stock analysts at Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for Stealth BioTherapeutics in a note issued to investors on Thursday, August 15th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.01) per share for the year.

Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04.

A number of other equities analysts have also weighed in on MITO. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Stealth BioTherapeutics in a research report on Friday, July 12th. Zacks Investment Research lowered Stealth BioTherapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $24.83.

Shares of NASDAQ:MITO opened at $10.79 on Monday. Stealth BioTherapeutics has a twelve month low of $10.70 and a twelve month high of $20.99. The stock’s 50 day moving average price is $12.17. The firm has a market capitalization of $423.51 million and a price-to-earnings ratio of -7.65.

An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 0.73% of the stock is currently owned by hedge funds and other institutional investors.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Read More: The role of implied volatility with call option volume

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit